Multicenter, Randomized, Phase III Study of a Single Dose of IncobotulinumtoxinA, Free from Complexing Proteins, in the Treatment of Glabellar Frown Lines
Authors:
- Jean CarruthersJCJean Carruthers
- William P. ColemanWCWilliam P. Coleman
- Lisa DonofrioLDLisa Donofrio
- Timothy FlynnTFTimothy Flynn
- Michael GoldMGMichael Gold
- Moritz HeinzMHMoritz Heinz
- Laura HarringtonLHLaura Harrington
- Derek JonesDJDerek Jones
- David McDanielDMDavid McDaniel
- Thomas RohrerTRThomas Rohrer
- Andrea SchlöbeASAndrea Schlöbe
- 1 April 2013
- journal article
- research article
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 39 (4) , 551-558
Abstract
Botulinum toxin type A is a proven, effective aesthetic treatment for glabellar frown lines. IncobotulinumtoxinA (NT 201, Xeomin/Xeomeen/Bocouture, Merz Pharmaceuticals GmbH, Frankfurt, Germany) is a 150-kDa botulinum toxin type A free of complexing proteins. To assess the efficacy and safety of incobotulinumtoxinA in a randomized, double-blind, placebo-controlled, Phase III study in patients with moderate to severe glabellar frown lines. Two hundred seventy-six patients were randomized 2:1 to receive a single injection of 20 U of incobotulinumtoxinA or placebo, respectively. Efficacy was assessed at day 30 using a Food and Drug Administration-mandated composite endpoint; a responder was defined as a patient with a 2-point or greater improvement in glabellar frown lines on a 4-point scale as assessed by investigator and patient. Safety was assessed periodically through Day 120. Treatment with a single dose of incobotulinumtoxinA was significantly superior to placebo in the treatment of glabellar frown lines at Day 30 using the composite endpoint (p < .001), with investigators and patients assessing glabellar frown lines as significantly more improved after incobotulinumtoxinA injection than with placebo (p < .001). IncobotulinumtoxinA was well tolerated. A single dose of 20 U of incobotulinumtoxinA demonstrated efficacy and safety in the treatment of glabellar frown lines using new Food and Drug Administration efficacy variables.Keywords
This publication has 9 references indexed in Scilit:
- Noninferiority of IncobotulinumtoxinA, Free from Complexing Proteins, Compared with Another Botulinum Toxin Type A in the Treatment of Glabellar Frown LinesDermatologic Surgery, 2010
- Botulinum Toxin in Facial Rejuvenation: An UpdateDermatologic Clinics, 2009
- Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: A double-blind, randomized studyJournal of the American Academy of Dermatology, 2006
- Prospective, Double-Blind, Randomized, Parallel-Group, Dose-Ranging Study of Botulinum Toxin Type A in Men with Glabellar RhytidsDermatologic Surgery, 2005
- Dose-Ranging Study of Botulinum Toxin Type A in the Treatment of Glabellar Rhytids in FemalesDermatologic Surgery, 2005
- A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar linesJournal of the American Academy of Dermatology, 2004
- Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Botulinum Toxin Type A for Patients with Glabellar LinesPlastic and Reconstructive Surgery, 2003
- A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar linesJournal of the American Academy of Dermatology, 2002
- Botulinum A Toxin Therapy: Neutralizing and Nonneutralizing Antibodies—Therapeutic ConsequencesExperimental Neurology, 1997